[Therapy-resistant hypertension--the value of aldosterone antagonists].
Uncontrolled studies suggest the benefits of an add-on antihypertensive therapy with an aldosterone receptor antagonist. However, it still must be clarified whether a PHA screening has a predictive value for the efficacy of a therapy with an aldosterone receptor antagonist. Before generally accepted recommendations can be made, a randomized, controlled study with aldosterone antagonists must prove that such a therapy is safer, tolerable and leads to better long-term blood pressure control as well as lower renal and cardiovascular morbidity and mortality.
Quack
I
I
Klinik für Nephrologie, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf. ivo.quack@med.uni-duesseldorf.de
Reincke
M
M
Rump
L C
LC
D000306:Adrenal Cortex Neoplasms / Q000150:complications / Q000175:diagnosis; D018246:Adrenocortical Adenoma / Q000150:complications / Q000175:diagnosis; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006929:Hyperaldosteronism / Q000175:diagnosis / Q000188:drug therapy*; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D000451:Mineralocorticoid Receptor Antagonists